StockWatch
·

Sastasundar Ventures Ltd Q2 FY27 Results

HEALTHXQ2 FY27 Results
Filing
Result:Steady· Market: Flat#One-off hit
MetricValue (₹ Cr)Q1 FY27Q2 FY26
Revenue484.098.3%60.7%
Total Income494.487.6%61.2%
Expenditure509.7211.4%56.7%
PBT-15.24871.6%18.2%
Net Profit-12.73740.6%17.6%
OPM-4.59%2.72pp2.97pp
NPM-2.57%3.00pp2.46pp
EPS-3.47533.8%187.0%
View full financials

Core Healthcare Network revenue grew 60.7% YoY to a 6-quarter high with its segment operating loss narrowing both YoY and QoQ, but the consolidated result remains a net loss (not a turnaround) and swung from Q1's thin profit back into loss almost entirely due to a one-off ₹6.15 Cr mark-to-market hit in the Financial Services book.

Q2 FY-2027 RESULTS · HEALTHX

Health X Platform Q2: loss narrows 18% YoY to ₹12.7 Cr, swings from Q1 profit on MTM hit

PAT +17.57% YoY · revenue +60.68% · margins expanding

14 Nov 2026 · 3 min read
Revenue

₹484.09 Cr

+60.68% YoY

PAT (consolidated)

₹-12.73 Cr

+17.57% YoY

Net margin

-2.57%

+2.5pp YoY

EPS

₹-3.47

Health X Platform (formerly Sastasundar Ventures) posted consolidated revenue of ₹484.09 Cr, up 60.7% YoY and 8.3% QoQ, almost entirely on the Healthcare Network segment (RetailerShakti/SastaSundar e-commerce distribution), whose segment revenue rose to ₹486.22 Cr from ₹307.95 Cr a year ago. Consolidated net loss (after tax, including minority interests) was ₹12.73 Cr — narrower than the year-ago ₹15.44 Cr loss (-17.6% YoY, ~16.7% on an adjusted basis excluding a ₹0.17 Cr prior-year exceptional item) — but a reversal from Q1 FY27's thin ₹1.99 Cr profit. Loss attributable to owners was ₹11.04 Cr, basic EPS -₹3.47 (not annualised).

The scoreboard

Q2 FY-2027 vs prior quarters

Consolidated P&L, ₹ Crore
Q2 FY-2027QoQYoY
Revenue₹484.09 Cr+8.3%+60.7%
Expenses₹509.72 Cr+11.4%+56.7%
PAT₹-12.73 Cr—+17.57%
Net margin-2.57%-3pp+2.5pp
EPS₹-3.47-533.8%-187%

The QoQ swing was driven almost entirely by the Financial Services segment, which booked a ₹6.15 Cr mark-to-market LOSS on fair-value changes in its investment book this quarter versus a ₹6.33 Cr gain in Q1 FY27 — a roughly ₹12.5 Cr swing that accounts for nearly the entire sequential deterioration. The core Healthcare Network business actually kept improving: its own segment operating loss narrowed to ₹13.87 Cr from ₹14.87 Cr (QoQ) and ₹15.45 Cr (YoY) even as revenue grew. Consolidated NPM was -2.57% (vs -5.03% YoY, +0.43% in Q1 FY27) and OPM (segment EBIT margin) was -4.01% (vs -7.57% YoY, -1.96% QoQ) — margins improving YoY but compressing sequentially, purely on the investment-book swing.

₹
261.48275.23288.98302.72316.47271.108-1109-0209-2510-2111-1211-13
The tape into the print — daily closes, last 3 months

The stock went into the print at ₹271.1, down 5.2% over the past month of trading.

₹ Cr
-20.48-3.1114.2631.6426.59Q1 FY26rev ₹298 Cr-15.44Q2 FY26rev ₹301 Cr0.37Q3 FY26rev ₹346 Cr-12.97Q4 FY26rev ₹374 Cr1.99Q1 FY27rev ₹447 Cr-12.73Q2 FY27rev ₹484 Cr
Quarterly consolidated PAT, ₹ Crore

For context: revenue is at a 6-quarter high.

Beyond the headline

What the summary numbers don't show

Standalone (holding-company-only) loss of ₹0.32 Cr on ₹0.09 Cr total income — nearly all business sits in subsidiaries

What management guided (1 FY-2027 call)
FY27 gross margin 8%+ target, approaching 12% at scale. RetailerShakti EBITDA positive expected Q3 FY27. July run rate ₹150 Cr. No EBITDA profitability for SastaSundar next 2-3 years.

No formal brokerage consensus for this quarter could be located for this micro-cap; third-party aggregators show FY27 consensus ROE near -13%, consistent with the company remaining loss-making. Management's prior concall (Aug 2026) guided RetailerShakti to turn EBITDA-positive in Q3 FY27 with a July run-rate of ₹150 Cr/month — this quarter's Healthcare Network revenue averaged roughly ₹162 Cr/month, slightly ahead of that marker, though the EBITDA milestone itself is a Q3 FY27 test not yet due. Management had separately flagged no EBITDA profitability for the core SastaSundar app for 2-3 years, consistent with the segment's continuing ₹13.87 Cr quarterly operating loss. The Board's June 2026 Composite Scheme of Arrangement amalgamating Microsec Resources, Innogrow Technologies and Sastasundar Healthbuddy into the company, effective April 1, 2026, remains pending regulatory approvals with no accounting impact yet reflected in this statement.

  • W1

    RetailerShakti/Healthcare Network EBITDA-positive target guided for Q3 FY27 — segment still posting a ₹13.87 Cr operating loss this quarter

  • W2

    Financial Services segment fair-value swings — a ₹12.5 Cr negative QoQ swing this quarter could reverse or repeat

  • W3

    Composite Scheme of Arrangement (MRPL/ITL/SHBL amalgamation) approval status and its pro forma impact once accounted for

Standalone is holding-co only (Core Investment Company, interest income ₹0.07 Cr) — consolidated is the real business and primary basis. Consolidated PAT of -₹12.73 Cr includes NCI; owners' share is -₹11.04 Cr (EPS -₹3.47, not annualised). No exceptional item this quarter; year-ago quarter carried a ₹0.17 Cr impairment exceptional item at Genu Path Labs (immaterial — adjusted vs raw YoY PAT improvement ~16.7% vs 17.6%). Step-down subsidiary Genu Path Labs flagged going-concern by auditors (net worth fully eroded) but auditor calls it not material to the Group. patQoQPct omitted — Q1 FY27 PAT base (+₹1.99 Cr) is too small for a meaningful percentage swing to -₹12.73 Cr.

Informational and educational content only. Not investment advice.